Alkermes Plc (ALKS) is a Healthcare · Drug Manufacturers - Specialty & Generic company listed on NASDAQ. Price $43.39 (-7.11%), Market cap $5.56B, P/E ratio 23.34, 52-week low–high $26.13 ~ $35.36.
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatm
Financial statements, price targets, institutional (13F) holdings and related news for Alkermes Plc are updated in real time on BlackAll Trade.
Alkermes Plc trades at $43.39 (-7.11%). Real-time quotes and charts are available on BlackAll Trade.
Alkermes Plc has a market cap of about $5.56B. Its P/E ratio is 23.34.
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the